Drugmaker Pfizer Beats Earnings Estimates, Targets $2.5 Billion in Additional Cost Cuts
- On Tuesday, August 4, 2026, Pfizer Inc reported better-than-expected second-quarter results and unveiled an additional $2.5 billion in cost-cutting initiatives to offset declining revenue.
- This additional reduction brings total targeted savings over the last three years to more than $10 billion, focusing on "network structure changes, product portfolio enhancements and additional operational efficiencies."
- Strong demand for anticoagulant Eliquis drove quarterly sales to $15 billion, while revenue from acquired products rose 25%. Astellas-partnered Padcev climbed 23% to $667 million and Lorbrena increased 37% to $354 million.
- The company raised its annual sales forecast to $60.5 billion to $62.5 billion. CEO Albert Bourla said "launched and acquired products performed well- our obesity programme is advancing with meaningful momentum."
- Pfizer anticipates stronger growth from 2028 as it reduces dependence on aging blockbusters, with investors monitoring the $10 billion Metsera acquisition for establishing a foothold in the obesity market.
26 Articles
26 Articles
Merck & Co., Inc. Q2 Earnings Call Highlights
Merck & Co., Inc. (NYSE:MRK) reported second-quarter revenue of $16.6 billion, up 5% from a year earlier, driven by oncology, animal health and contributions from newer product launches. Revenue increased 4% excluding foreign exchange, according to Chief Financial Officer Caroline Litchfield. T
The Economic Times
Times of IndiaDrugmaker Pfizer beats earnings estimates, targets $2.5 billion in additional cost cuts
Pfizer has reported impressive second-quarter earnings, driven by the success of Eliquis and newly acquired pharmaceutical products. The company is planning $2.5 billion in cost-saving measures expected to be in place by 2029. With a focus on innovative treatments, Pfizer aims to reduce reliance on older, high-grossing medications and looks forward to a notable growth revival post-2028, actively pushing its obesity treatment initiatives.
American pharmaceutical company Pfizer, which earned billions from its coronavirus drugs in recent years, is now seeing its financial results deteriorate. The company suffered a net loss of $248 million in the second quarter, compared to a net profit of nearly $3 billion in the same period last year, it was announced on Tuesday.
Coverage Details
Bias Distribution
- 59% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
